Investec Switzerland. The U.K.’s decision to leave the European Union poses a threat to research and development in the pharmaceutical industry, Roche Holding AG Chief Executive Officer Severin Schwan said. © Lucaderoma | Dreamstime.com A departure would mean the country would have to set up its own system for approving drugs for sale, a job now done for bloc members by the European Medicines Agency. That could put U.K. patients at risk of not getting access to medicines as...
Read More »Roche CEO worried about U.K. drug research following Brexit
Investec Switzerland. The U.K.’s decision to leave the European Union poses a threat to research and development in the pharmaceutical industry, Roche Holding AG Chief Executive Officer Severin Schwan said. © Lucaderoma | Dreamstime.com A departure would mean the country would have to set up its own system for approving drugs for sale, a job now done for bloc members by the European Medicines...
Read More »